CRISPR Base Editing (PCSK9 - Verve-101)

Type: gene_editing

Status: Investigational (UK/NZ trials)

Developer: Verve Therapeutics

Breakthrough Summary

No summary available.

Mechanism of Action

Single-dose base editing to permanently lower LDL cholesterol by silencing PCSK9

Year: 2024-2026